Current chemotherapy options for thymic epithelial neoplasms

Bibliography

• ENGELS EA, PFEIFFER RM: Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int. J. Cancer (2003) 105(4):546–551.
   PubMed Web of Science ®Google Scholar
• •Population-based epidemiological study.
   Google Scholar
• LI H, LOEHRER PJ Sr, HISADA M, HENLEY J, WHITBY D, ENGELS EA: Absence of human T-cell lymphotropic virus type I and human foamy virus in thymoma. Br. J. Cancer (2004) 90(11):2181–2185.
   PubMedGoogle Scholar
• CHEN PC, PAN CC, YANG AH, WANG LS, CHIANG H: Detection of Epstein-Barr virus genome within thymic epithelial tumours in Taiwanese patients by nested PCR, PCR in situ hybridization, and RNA in situ hybridization. J. Pathol (2002) 197(5):684–688.
   PubMedGoogle Scholar
• ROSAI J, SOBIN LH: Histological typing of tumors of the thymus. In: International Histological Classification of Tumors.( 2nd Edition) World Health Organization, Springer Co., New York, NY, USA (1999):9.
   Google Scholar
• CHEN G, MARX A. WEN-HU C et al.: New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer (2002) 95(2):420–429.
   Google Scholar
• INOUE M, STAROSTIK P, ZETTL A et al.: Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res. (2003) 63(13):3708–3715.
   PubMedGoogle Scholar
• OKUMURA M, OHTA M, TATEYAMA H et al.: The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer (2002) 94(3):624–6327.
   PubMed Web of Science ®Google Scholar
• ••Large retrospective analysis confirmingcorrelation of WHO histological classification with prognosis.
   Google Scholar
• STROBEL P, BAUER A, PUPPE B et al.: Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J. Clin. OncoL (2004) 22(8):1501–1509.
   PubMedGoogle Scholar
• ZETTL A, STROBEL P, WAGNER K et al.: Recurrent genetic aberrations in thymoma and thymic carcinoma. Am. J. PathoL (2000) 157(1):257–266.
   PubMedGoogle Scholar
• HIRABAYASHI H, FUJII Y, SAKAGUCHI M et al.: p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int. J. Cancer (1997) 73(5):639–644.
   PubMed Web of Science ®Google Scholar
• SASAKI H, KOBAYASHI Y, TANAHASHI M et al.: Ets-1 gene expression in patients with thymoma. Jpn. J. Thorac. Cardiovasc. Surg. (2002) 50(12):503–507.
   PubMedGoogle Scholar
• SASAKI H, YUKIUE H, KOBAYASHI Y, FUKAI I, FUJII Y: Cten mRNA expression is correlated with tumor progression in thymoma. Tumour Biol. (2003) 24(5):271–274.
   PubMedGoogle Scholar
• SASAKI H, IDE N, SENDO F et al.: Glycosylphosphatidyl inositol-anchored protein (GPI-80) gene expression is correlated with human thymoma stage. Cancer Sci. (2003) 94(9):809–813.
   PubMedGoogle Scholar
• MASAOKA A, MONDEN Y, NAKAHARA K, TANIOKA T: Follow-up study of thymomas with special reference to their clinical stages. Cancer (1981) 48(11):2485–2492.
   PubMed Web of Science ®Google Scholar
• KOGA K, MATSUNO Y, NOGUCHI M et al.: A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. PathoL Int. (1994) 44(5):359–567.
   PubMed Web of Science ®Google Scholar
• •Proposed modified Masaoka staging for thymic neoplasms.
   Google Scholar
• REGNARD JF, MAGDELEINAT P, DROMER C et al.: Prognostic factors and long-term results after thymoma resection: a series of 307 patients. J. Thorac. Cardiovasc. Surg. (1996) 112(2):376–84.
   PubMed Web of Science ®Google Scholar
• YAGI K, HIRATA T, FUKUSE T et al.: Surgical treatment for invasive thymoma, especially when the superior vena cava is invaded. Ann Thorac. Surg (1996) 61(2):521–524.
   PubMedGoogle Scholar
• KIRSCHNER PA: Reoperation on the thymus. A critique. Chest Surg. Clin. N Am. (2001) 11(2):439–445.
   PubMedGoogle Scholar
• REGNARD JF, ZINZINDOHOUE F, MAGDELEINAT P et al.: Results of re-resection for recurrent thymomas. Ann. Thorac. Surg. (1997) 64(6):1593–1598.
   PubMedGoogle Scholar
• BLUMBERG D, PORT JL, WEKSLER B et al.: Thymoma: a multivariate analysis of factors predicting survival. Ann. Thorac. Surg. (1995) 60(4):908–913.
   PubMedGoogle Scholar
• CURRAN WJ JR, KORNSTEIN MJ, BROOKS JJ, TURRISI AT 3rd: Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J. Clin. OncoL (1988) 6(10:1722–1727.
   PubMedGoogle Scholar
• FUJIMURA S, KONDO T, HANDA M et al.: Results of surgical treatment for thymoma based on 66 patients. J. Thorac. Cardiovasc. Surg. (1987) 93(5):708–714.
   PubMedGoogle Scholar
• NAKAHARA K, OHNO K, HASHIMOTO J et al.: Thymoma: results with complete resection and adjuvant postoperative irradiation in 141 consecutive patients. J. Thorac. Cardiovasc. Surg. (1988) 95(6):1041–1047.
   PubMed Web of Science ®Google Scholar
• OGAWA K, UNO T, TOITA T et ell.: Postoperative radiotherapy for patients with completely resected thymoma: a multi-institutional, retrospective review of 103 patients. Cancer (2002) 94(5):1405–1413.
   Google Scholar
• POLLACK A, KOMAKI R, COX JD et al.: Thymoma: treatment and prognosis. Int. J. Radiat. OncoL Biol. Phys. (1992) 23(5):1037–1043.
   PubMedGoogle Scholar
• QUINTANILLA-MARTINEZ L, WILKINS EW Jr, CHOI N et al.: Thymoma. Histologic subclassification is an independent prognostic factor. Cancer (1994) 74(2):606–617.
   Google Scholar
• SINGHAL S, SHRAGER JB, ROSENTHAL DI, LIVOLSI VA, KAISER LR: Comparison of stages I-II thymoma treated by complete resection with or without adjuvant radiation. Ann. Thorac. Surg. (2003) 76(5):1635–1641.
   PubMedGoogle Scholar
• •Recent paper analysing the role for radiation therapy in stage I and II thymic neoplasms.
   Google Scholar
• KOHMAN LJ: Controversies in the management of malignant thymoma. Chest (1997) 112(4 Suppl):2965–3005.
   Google Scholar
• HANIUDA M, MIYAZAWA M, YOSHIDA K et al.: Is postoperative radiotherapy for thymoma effective? Ann. Surg (1996) 224(2):219–224.
   Google Scholar
• MANGI AA, WRIGHT CD, ALLAN JS et al.: Adjuvant radiation therapy for stage II thymoma. Ann. Thorac. Surg. (2002) 74(4):1033–1037.
   PubMedGoogle Scholar
• KONDO K, MONDEN Y: Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann. Thorac. Surg. (2003) 76(3):878–884.
   PubMed Web of Science ®Google Scholar
• URGESI A. MONETTI U, ROSSI G, RICARDI U, CASADIO C: Role of radiation therapy in locally advanced thymoma. Radiother. OncoL (1990) 19(3):273–280.
   PubMed Web of Science ®Google Scholar
• ARAKAWA A, YASUNAGA T, SAITOH Y et al.: Radiation therapy of invasive thymoma. Int. J. Radiat. OncoL Biol. Phys. (1990) 18(3):529–534.
   PubMedGoogle Scholar
• GRIPP S, HILGERS K, WURM R, SCHMITT G: Thymoma: prognostic factors and treatment outcomes. Cancer (1998) 83(8):1495–1503.
   PubMedGoogle Scholar
• CIERNIK IF, MEIER U, LUTOLF UM: Prognostic factors and outcome of incompletely resected invasive thymoma following radiation therapy. J. Clin. OncoL (1994) 12(7):1484–1490.
   PubMedGoogle Scholar
• MORNEX F, RESBEUT M, RICHAUD P et al.: Radiotherapy and chemotherapy for invasive thymomas: a multicentric retrospective review of 90 cases. The FNCLCC trialists. Federation Nationale des Centres de Lutte Contre le Cancer. Int. J. Radiat. OncoL Biol. Phys. (1995) 32(3):651–659.
   Google Scholar
• URGESI A, MONETTI U, ROSSI G et al.: Aggressive treatment of intrathoracic recurrences of thymoma. Radiother. OncoL (1992) 24(4):221–225.
   PubMedGoogle Scholar
• ENG TY, FULLER CD, JAGIRDAR J, BAINS Y, THOMAS CR Jr: Thymic carcinoma: state of the art review. Int. J. Radiat. OncoL Biol .Phys. (2004) 59(3):654–664.
   PubMedGoogle Scholar
• ••Comprehensive review of chemotherapyfor thymic carcinoma.
   Google Scholar
• CAMPBELL MG, POLLARD R, AL-SARRAF M: A complete response in metastatic malignant thymoma to cis-platinum, doxorubicin and cyclophosphamide: a case report. Cancer (1981) 48(6):1315–1317.
   PubMedGoogle Scholar
• CHAHINIAN AP, BHARDWAJ S, MEYER RJ et al.: Treatment of invasive or metastatic thymoma: report of eleven cases. Cancer (1981) 47(7):1752–1761.
   PubMedGoogle Scholar
• DAUGAARD G, HANSEN HH, RORTH M: Combination chemotherapy for malignant thymoma. Ann. Intern. Med. (1983) 99(2):189–190.
   PubMedGoogle Scholar
• GOLDEL N, BONING L, FREDRIK A et al.: Chemotherapy of invasive thymoma. A retrospective study of 22 cases. Cancer (1989) 63(8):1493–1500.
   Google Scholar
• BONOMI PD, FINKELSTEIN D, AISNER S, ETTINGER D: EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma. Am. J. Clin. OncoL (1993) 16(4):342–345.
   PubMedGoogle Scholar
• HIGHLEY MS, UNDERHILL CR, PARNIS FX et al.: Treatment of invasive thymoma with single-agent ifosfamide. Clin. Oncol. (1999) 17(9):2737–2744.
   Google Scholar
• LOEHRER SR, KIM K, AISNER SC et al.: Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J. Clin. OncoL (1994) 12(6):1164–1168.
   Google Scholar
• •Report establishing CAP as active regimen for advanced-stage thymoma.
   Google Scholar
• LOEHRER PJ SR, JIROUTEK M, AISNER S et al.: Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer (2001) 91(11):2010–2015.
   PubMedGoogle Scholar
• GIACCONE G, ARDIZZONI A, KIRKPATRICK A et al.: Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Clin. Oncol (1996) 14(3):814–820.
   Google Scholar
• FORNASIERO A, DANIELE O, GHIOTTO C et al.: Chemotherapy for invasive thymoma. A 13-year experience. Cancer (1991) 68(1):30–33.
   Google Scholar
• UMEMURA S, SEGAWA Y, FUJIWARA K et al.: A case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy. Jpn. j Clin. Oncol (2002) 32(7):262–265.
   PubMedGoogle Scholar
• SANDLER A, FOX S, MEYERS T et al.: Paclitaxel plus gallium nitrate and filgrastim in patients with refractory malignancies: a phase I trial. Am. J. Clin. Oncol (1998) 21(2):180–184.
   PubMedGoogle Scholar
• JAN N, VILLANI GM, TRAMBERT J et al.: A novel second line chemotherapy treatment of recurrent thymoma. Med. Oncol (1997) 14(3-4):163–168.
   PubMedGoogle Scholar
• TERMEER A, VISSER FJ, MRAVUNAC M: Regression of invasive thymoma following corticosteroid therapy. Neth. J. Med. (2001) 58(4):181–184.
   PubMedGoogle Scholar
• PALMIERI G, LASTORIA S, COLAO A et al.: Successful treatment of a patient with a thymoma and pure red-cell aplasia with octreotide and prednisone. N Engl J. Med. (1997) 336(4):263–265.
   PubMedGoogle Scholar
• PALMIERI G, MONTELLA L, MARTIGNETTI A et al.: Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer (2002) 94(5):1414–1420.
   PubMed Web of Science ®Google Scholar
• •Confirmation of efficacy of octreotide and prednisone in treatment of thymomas.
   Google Scholar
• LOEHRER PJ Sr, WANG W, JOHNSON DH, AISNER SC, ETTINGER DS: Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J. Clin. Oncol (2004) 22(2):293–299.
   PubMedGoogle Scholar
• LOEHRER PJ SR, CHEN M, KIM K et al.: Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. Clin. Oncol. (1997) 15(9):3093–3099.
   Google Scholar
• •Prospective trial confirming feasibility of combination chemoradiation regimen.
   Google Scholar
• MACCHIARINI P, CHELLA A, DUCCI F et al.: Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer (1991) 68(4):706–713.
   PubMedGoogle Scholar
• VENUTA F, RENDINA EA, PESCARMONA EO et al.: Multimodality treatment of thymoma: a prospective study. Ann. Thorac. Surg. (1997) 64(6):1585–1591.
   PubMedGoogle Scholar
• PESCARMONA E, RENDINA EA, VENUTA F et al.: Analysis of prognostic factors and clinicopathological staging of thymoma. Ann. Thorac. Surg. (1990) 50(4):534–538.
   PubMedGoogle Scholar
• VENUTA F, RENDINA EA, LONGO F et al.: Long-term outcome after multimodality treatment for stage III thymic tumors. Ann. Thorac. Surg. (2003) 76(6):1866–1872.
   PubMedGoogle Scholar
• REA F, SARTORI F, LOY M et al.: Chemotherapy and operation for invasive thymoma. J.Thorac. Cardiovasc. Surg. (1993) 106(3):543–549.
   PubMedGoogle Scholar
• REA F, MARULLI G, GIRARDI R et ell.: Long-term survival and prognostic factors in thymic epithelial tumours. Eur. j Cardiothorac. Surg (2004) 26(2):412–418.
   Google Scholar
• SHIN DM, WALSH GL, KOMAKI R et al.: A multidisciplinary approach to therapy for unresectable malignant thymoma. Ann. Intern. Med. (1998) 129(2):100–104.
   PubMedGoogle Scholar
• KIM ES, PUTNAM JB, KOMAKI R et al.: Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer (2004) 44(3):369–379.
   PubMed Web of Science ®Google Scholar
• •Prospective study of trimodality therapy for unresectable stage III thymoma.
   Google Scholar
• HAYASHI Y, ISHII N, OBAYASHI C et al.: Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21. Wrchows Arch. (1995) 426(1):43–50.
   PubMedGoogle Scholar
• HENLEY JD, KOUKOULIS GK, LOEHRER PJ SR: Epidermal growth factor receptor expression in invasive thymoma. J. Cancer. Res. Clin. Oncol (2002) 128(3):167–170.
   PubMedGoogle Scholar
• IONESCU DN, SASATOMI E, CIEPLY K, NOLA M, DACIC S: Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer (2005) 103(3):630–636.
   PubMedGoogle Scholar
• PAO W, MILLER V ZAKOWSKI M et al.: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA (2004) 101(36):13306–13311.
   Google Scholar
• PAN CC, CHEN PC, CHIANG H: KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J. Pathol (2004) 202(3):375–381.
   PubMed Web of Science ®Google Scholar
• HENLEY JD, CUMMINGS OW, LOEHRER PJ Sr: Tyrosine kinase receptor expression in thymomas. j Cancer. Res. Clin. Oncol (2004) 130(4):222–224.
   PubMedGoogle Scholar
• STROBEL P, HARTMANN M, JAKOB A et al.: Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J. Med. (2004) 350(25):2625–2626.
   PubMedGoogle Scholar
• PAN CC, CHEN PC, WANG LS, LEE JY, CHIANG H: Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopatho/ogy (2003) 43(2):165–172.
   PubMedGoogle Scholar
• TOMITA M, MATSUZAKI Y, EDAGAWA M et al.: Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. Thorac. Cardiovasc. Surg. (2002) 124(3):493–498.
   Google Scholar
• SASAKI H, YUKIUE H, KOBAYASHI Y et al.: Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Surg. Today (2001) 31(11):1038–1040.
   PubMedGoogle Scholar
• TATEYAMA H, EIMOTO T, TADA T et al.: Apoptosis, bc1-2 protein, and Fas antigen in thymic epithelial tumors. Mod. Pathol (1997) 10(10):983–991.
   PubMedGoogle Scholar
• HIROSHIMA K, IYODA A, TOYOZAKI T et al.: Proliferative activity and apoptosis in thymic epithelial neoplasms. Mod. PathoL (2002) 15(12):1326–1332.
   PubMedGoogle Scholar
• BLANC-BRUDE OP, MESRI M, WALL NR et al.: Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin. Cancer. Res. (2003) 9(7):2683–2692.
   PubMedGoogle Scholar